Alumis Employees

As of December 31, 2025, Alumis had 224 total employees, including 221 full-time and 3 part-time employees. The number of employees increased by 54 or 31.76% compared to the previous year.

Employees

224

Change (1Y)

Growth (1Y)

31.76%

Revenue / Employee

$107,366

Profits / Employee

-$1,086,272

Market Cap

3.06B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	224	54	31.76%
Dec 31, 2024	170	61	55.96%
Dec 31, 2023	109	-	-

Related Stocks

Company Name	Employees
Arcus Biosciences	601
Denali Therapeutics	503
Arcutis Biotherapeutics	354
Dyne Therapeutics	258
Structure Therapeutics	220
Relay Therapeutics	192
Catalyst Pharmaceuticals	182
Edgewise Therapeutics	146

Employee Rankings

ALMS News

4 weeks ago - Alumis Transcript: Study update - Transcripts
4 weeks ago - Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis - GlobeNewsWire
5 weeks ago - Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - GlobeNewsWire
5 weeks ago - Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
7 weeks ago - Alumis Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
2 months ago - Alumis to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
2 months ago - Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference - Transcripts
2 months ago - Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts

More News